🇺🇸 FDA

Company profile · Sponsor

Blueprint

Blueprint Medicines (Netherlands) B.V.

EB0A4C6 · EMA pharma EU
Pipeline
6
Drugs
0
Patents
0

Quick answer

Blueprint (EB0A4C6) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EB0A4C6
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (6)

Search pipeline →

  1. Placebo tablets, ELENESTINIB, ELENESTINIB, ELENESTINIB, ELENESTINIB

    Blueprint

    Indolent Systemic Mastocytosis and SSM

    phase 3 small molecule active

    1 trial

  2. AZACITIDINE

    Blueprint

    Advanced Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  3. Avapritinib, Avapritinib, Avapritinib

    Blueprint

    Solid Tumors Dependent on KIT or PDGFRA Signaling

    phase 2 small molecule active

    1 trial

  4. Avapritinib, Avapritinib, Avapritinib Placebo Tablets

    Blueprint

    Indolent Systemic Mastocytosis (ISM)

    phase 2 small molecule active

    1 trial

  5. Placebo matching BLU-808, tablet, BLU-808, BLU-808

    Blueprint

    Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  6. Avapritinib, Avapritinib

    Blueprint

    Systemic Mastocytosis

    approved small molecule active

    1 trial

Frequently asked questions

What is Blueprint?

Blueprint (EB0A4C6) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Blueprint sponsor?

We track 6 ClinicalTrials.gov-linked programs for Blueprint, including Placebo tablets, ELENESTINIB, ELENESTINIB, ELENESTINIB, ELENESTINIB and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Blueprint company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.